Drug profile · INN
agalsidase beta
FABRAZYME
agalsidase beta (FABRAZYME) is a globotriosylceramide hydrolytic enzyme. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — agalsidase beta
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
agalsidase beta (FABRAZYME) is a globotriosylceramide hydrolytic enzyme. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Globotriosylceramide hydrolytic enzyme
Primary target: Globotriosylceramide
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is agalsidase beta?
agalsidase beta (FABRAZYME) is a globotriosylceramide hydrolytic enzyme. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for agalsidase beta?
FABRAZYME is a marketed brand name for agalsidase beta. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of agalsidase beta?
agalsidase beta has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.